Technical Outlook Strengthens to Bullish
The primary catalyst for the upgrade stems from a marked improvement in Mankind Pharma’s technical grade, which has shifted from mildly bullish to bullish. Key technical indicators underpinning this change include a bullish Moving Average Convergence Divergence (MACD) on the weekly chart, supported by bullish Bollinger Bands on both weekly and monthly timeframes. Daily moving averages also signal a positive momentum, reinforcing the upward trend.
While some indicators such as the Relative Strength Index (RSI) and Dow Theory show no definitive trend, and the KST and On-Balance Volume (OBV) present mildly bearish signals on weekly charts, the overall technical consensus favours a bullish stance. This technical strength is reflected in the stock’s recent price action, with the current price at ₹2,404.95, up 1.75% on the day, nearing its 52-week high of ₹2,726.75.
Financial Trend Displays Robust Growth and Efficiency
Mankind Pharma’s financial performance in Q4 FY25-26 has been a significant factor in the rating upgrade. The company reported an operating profit to net sales ratio of 27.01%, indicating strong operational efficiency. Its operating profit to interest coverage ratio reached a high of 6.56 times, underscoring a solid ability to service debt. The profit before tax excluding other income stood at ₹568.04 crores, marking a healthy profitability level.
Long-term financial trends are equally encouraging. Operating profit has grown at an annualised rate of 20.15%, while the company maintains a high return on capital employed (ROCE) of 20.79%, signalling effective capital utilisation. The debt to EBITDA ratio remains low at 1.74 times, reflecting prudent leverage management and financial stability.
Under the radar no more! This Large Cap from Cement is emerging from turnaround with solid fundamentals intact. Discover it while it's still relatively hidden!
- - Hidden turnaround gem
- - Solid fundamentals confirmed
- - Large Cap opportunity
Quality Metrics and Institutional Confidence
Mankind Pharma’s quality parameters remain strong, supported by high management efficiency and consistent returns. The company’s Mojo Score stands at 72.0, with a Mojo Grade upgraded to Buy from Hold as of 18 June 2026. This reflects a favourable assessment of the company’s fundamentals and market positioning within the Pharmaceuticals & Biotechnology sector.
Institutional holdings are robust at 24.7%, indicating confidence from sophisticated investors who typically conduct thorough fundamental analysis. This institutional backing provides a degree of stability and suggests that the stock is well-regarded among professional market participants.
Valuation: Fair but Expensive Relative to Growth
Despite the positive outlook, valuation remains a nuanced factor. Mankind Pharma trades at an enterprise value to capital employed ratio of 5.0, which is considered expensive relative to its ROCE of 13.3% on a trailing basis. The price-to-earnings growth (PEG) ratio is notably high at 33, signalling that the market may be pricing in substantial future growth expectations.
However, when compared to peer averages and historical valuations, the stock is trading at a fair value. Investors should weigh the premium valuation against the company’s strong operational metrics and growth trajectory. The stock’s returns over various periods further support this view: a 9.5% year-to-date return versus a negative 9.17% for the Sensex, and a 48.25% gain over three years compared to the Sensex’s 22.13%.
Comparative Performance and Market Context
Over the last year, Mankind Pharma has delivered a 2.34% return, outperforming the BSE500 index which declined by 4.95%. The stock’s resilience is further highlighted by its positive year-to-date return of 9.5%, contrasting with the broader market’s negative 9.17% performance. This relative strength underscores the company’s defensive qualities and growth potential within the pharmaceutical sector.
Shorter-term returns show some volatility, with a 1-month decline of 3.66% against a 2.78% gain in the Sensex, and a 1-week gain of 1.4% lagging the Sensex’s 4.85%. These fluctuations are typical in mid-cap stocks but are offset by the company’s solid fundamentals and improving technical indicators.
Mankind Pharma Ltd caught your attention? Explore our comprehensive research report with in-depth analysis of this mid-cap Pharmaceuticals & Biotechnology stock – fundamentals, valuations, financials, and technical outlook!
- - Comprehensive research report
- - In-depth mid-cap analysis
- - Valuation assessment included
Risks and Considerations
Investors should remain mindful of certain risks despite the upgrade. The company’s PEG ratio of 33 suggests that expectations for earnings growth are very high, which could lead to valuation pressure if growth slows. Additionally, while the ROCE is strong at 20.79% for the latest quarter, the trailing ROCE of 13.3% indicates some variability in returns on capital.
Moreover, the stock’s technical indicators, while predominantly bullish, include some mildly bearish signals on weekly KST and OBV, which could signal short-term volatility. The stock’s valuation premium relative to some peers also warrants caution, especially in a sector sensitive to regulatory changes and competitive pressures.
Conclusion: Upgrade Reflects Balanced Optimism
The upgrade of Mankind Pharma Ltd to a Buy rating is a reflection of its improved technical momentum, strong quarterly financial results, and solid long-term growth prospects. The company’s operational efficiency, low leverage, and institutional support provide a robust foundation for future performance. While valuation remains on the higher side, the stock’s consistent outperformance relative to the Sensex and sector peers justifies the positive outlook.
Investors seeking exposure to the Pharmaceuticals & Biotechnology sector may find Mankind Pharma an attractive mid-cap candidate, balancing growth potential with quality fundamentals and improving market sentiment.
Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →
